New report sheds light on hospital price variation
Ever wonder why you can't get a straight answer about how much a test or procedure in the hospital? This new report has answers. More
Blog
Slow progress in reducing breast cancer overscreening
American women are still getting too many mammograms. Despite recommendations from the US Preventive Services Task Force and the American Cancer Society against routine screening for breast cancer before age 50, the rates of mammogram screening have not changed significantly in the past ten years. In a recent JAMA Clinical Update, Dr. Nancy Keating and […] More
When doing everything means doing less
For Randi Oster, the hardest part of her father's cancer wasn't getting him through treatment. It was getting his doctors to listen to what he wanted. More
The cart is driving the horse: Misguided performance measures
When it comes to measuring quality, there is a huge disconnect between payers and physicians. A recent analysis in the New England Journal of Medicine lends support to the physicians' side of the issue. More
Belief and evidence: How framing health news matters
Gina Kolata misrepresents the debate on tPA for strokes by painting the issue as evidence versus belief. More
Hidden influence: Financial conflicts you might have missed
Recent conflicts of interest in medicine and health policy you probably missed... More
Industry payments to doctors: Opioids are the tip of the iceberg
A closer look at the hundreds of millions that pharma spends on payments to physicians. More
Industry payments to doctors: Opioids are the tip of the iceberg
A closer look at the hundreds of millions that pharma spends on payments to physicians. More
Meeting people where they are for primary care
How can we increase access to primary care in underserved areas? How about meeting patients where they are? More
What we know and don’t know about overdiagnosis
A study in The BMJ shows that overdiagnosis research is growing but discrepancies in definitions and measurement complicate the evidence. More
What’s the harm in excessive cancer screening?
Not only does too much cancer screening lead to false positives and overtreatment, it can also skew our data. More
Has “Less is More” gone too far? The New England Journal says it has.
Are we oversimplifying the discussion when it comes to overuse? In a NEJM editorial, Lisa Rosenbaum argues that "less is more" can be a slippery slope. Here's what we thought about her controversial piece. More
As dangerous as opioids: Benzo overprescription becoming a crisis
Opioids aren't the only drug being dangerously overprescribed... More
Hospitals are making a fortune on Wall Street
The nation's largest not-for-profit hospital systems reaped more than $21 billion last year from their Wall Street investments, mergers and other investment options, according to an Axios analysis of financial documents. More
New blood pressure guidelines increases danger of overtreatment
Why the new lower blood pressure target could be harmful to patients... More
Can one study change clinical practice?
Professor Doug McKell explains why ORBITA might not be enough to reduce unnecessary stents. More
HPV protection or cancer vaccine? Putting Gardasil in context
Why was Gardasil originally marketed as a cervical cancer vaccine? Professor Samantha Gottlieb explains. More
INTERVIEW: Dr. David Brown on startling stent study
Cardiologist David Brown addresses some of the criticisms of the controversial ORBITA trial. More
Value-based care initiatives floundering in a broken system
Does value-based care stand a chance against the fee-for-service Goliath? More
Lown president, cardiologist, reacts to stent controversy
A study in The Lancet this week has rocked the world of cardiology by showing that stents are no better than a placebo in relieving chest pain. More